Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-16

Cardiff Oncology (CRDF)

CEO Mark Erlander was paid $3,023,344 in fiscal year 2025, ↑ up 25.9% from fiscal year 2024, the 1st percentile of its disclosed peer group (SEC filing 0001213037-26-000006 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,023,344 ↑
Mark Erlander total, FY2025
1st
CEO pay percentile vs peers
—
CEO-to-median pay ratio
90.62%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Mark Erlander (Chief Executive Officer), FY2025 total compensation $3,023,344 (base salary $635,000) [exec_comp, SEC accession 0001213037-26-000006, filed 2026-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

CRDF's next annual pay disclosure, estimated April 17, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Mark Erlander$635,000$0$0$2,266,106$122,238$0$0$3,023,344
Chief Executive Officer
Roger Sidhu279,370001,920,27574,160002,273,805
Chief Medical Officer
James Levine490,00000993,87561,740001,545,615
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Mark Erlander$3,023,344$2,401,376$1,547,772↑ +621,968
Roger Sidhu2,273,805———
James Levine1,545,6151,266,364917,719↑ +279,251

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Cardiff Oncology's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CRDF reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against CRDF
2 companies name CRDF as a compensation peer

Each company listed discloses CRDF in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CRDF in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
James LevineCFO$1,545,615
Mark ErlanderCEO$3,023,344
Roger SidhuChief Medical Officer$2,273,805
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Gary W. PaceIndependent Director$184,170
James O. ArmitageIndependent Director$175,670
Lale WhiteIndependent Director$189,170
Mani MohindruDirector$183,670
Renee P. TannenbaumIndependent Director$181,670
Rodney S. MarkinIndependent Director$225,670
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Ajay AggarwalChief Operating Officer2026-04-27A400,000$0$0Derivative, Class A CommonForm 4 ↗
Gary W. PaceDirector2026-06-11A40,56500Derivative, Class A CommonForm 4 ↗
Rodney S. MarkinDirector2026-06-11A40,56500Derivative, Class A CommonForm 4 ↗
Renee P. TannenbaumDirector2026-06-11A40,56500Derivative, Class A CommonForm 4 ↗
Lale WhiteDirector2026-06-11A40,56500Derivative, Class A CommonForm 4 ↗
James O. ArmitageDirector2026-06-11A40,56500Derivative, Class A CommonForm 4 ↗
Mani MohindruDirector2026-06-18A24,703129,891CommonForm 4 ↗
Gary W. PaceDirector2026-06-18A30,000136,600CommonForm 4 ↗
Mani MohindruDirector2026-07-14A34,364150,000CommonForm 4 ↗
Gary W. PaceDirector2026-07-14A687,28511,000,000CommonForm 4 ↗
Gary W. PaceDirector2026-07-14A687,28500Derivative, Class A CommonForm 4 ↗
Mani MohindruDirector2026-07-14A34,36400Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
James LevineOption—————$993,875
Mark ErlanderOption—————2,266,106
Roger SidhuOption—————1,920,275
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
James Levine$0$0$993,8750.0%
Mark Erlander002,266,1060.0%
Roger Sidhu001,920,2750.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
James LevineOption61,7101.72—
Mark ErlanderOption150,6451.72—
Mark ErlanderOption286,8753.51—
James LevineOption10,6262.5—
Mark ErlanderOption23,1332.5—
James LevineOption332,6213.58—
Mark ErlanderOption758,4003.58—
James LevineOption115,3173.51—
Roger SidhuOption600,0003.86—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation philosophy is to offer our employees compensation and benefits that are competitive and that meet our goals of attracting, retaining and motivating highly skilled employees so that we can achieve our financial and strategic objectives.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policyTrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1117,120,1761,772,185437,04990.62%Passed
20252025-06-2618,881,8172,576,465539,75587.99%Passed
20242024-06-2013,280,9192,131,944410,74786.17%Passed
20232023-06-1511,916,2102,419,195292,66583.12%Passed
20222022-06-097,931,0267,356,1862,020,45245.82%Failed
20192019-06-06827,83687,82249,87190.41%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1190.62%a
20252025-06-2687.99%b
20242024-06-2086.17%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Rodney S. MarkinIndependent · Audit · Compensation$119,000$0$106,670—$0$225,670
Lale WhiteIndependent · Audit (Chair) · Compensation82,5000106,670—0189,170
Gary W. PaceIndependent · Nominating/Governance (Chair)77,5000106,670—0184,170
Mani MohindruEmployee director77,0000106,670—0183,670
Renee P. TannenbaumIndependent · Compensation (Chair) · Nominating/Governance75,0000106,670—0181,670
James O. ArmitageIndependent · Audit · Nominating/Governance69,0000106,670—0175,670
09

Board fee structure and ownership guideline

Annual cash retainer$65,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)16,000 / 10,000 / 8,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$500,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$500,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Cardiff Oncology names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Cardiff Oncology.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Structure2025Raymond Stevens$672,094$2,387,996$4,846,926$508,871$8,429,887
2Cardiff Oncology2025Mark Erlander635,00002,266,106122,2383,023,344

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Cardiff Oncology35%Options 100not disclosedAon
Structure125%Options 67 · RSU 33NoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Cardiff Oncology in fiscal 2025?
As disclosed, Mark Erlander (Chief Executive Officer) was the highest-paid executive at Cardiff Oncology in fiscal 2025, with total compensation of $3,023,344.
How does Cardiff Oncology's chief executive pay compare to its disclosed peer group?
As disclosed, Mark Erlander's total compensation ranked at the 1st percentile of Cardiff Oncology's disclosed peer group.
How did shareholders vote on Cardiff Oncology's executive compensation?
As disclosed, 90.62% of shareholders supported Cardiff Oncology's executive compensation in the latest say-on-pay vote.
How much does Cardiff Oncology spend in total on board compensation for fiscal 2025?
As disclosed, Cardiff Oncology reported total board compensation of $500,000 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Mark ErlanderDEF 14A2026-04-230001213037-26-000006Section “Summary Compensation Table”. As printed: 3,023,344. Filing ↗machine: r2 · c16 · span 873925–873934
2Section 01, Roger SidhuDEF 14A2026-04-230001213037-26-000006Section “Summary Compensation Table”. As printed: 2,273,805. Filing ↗machine: r6 · c15 · span 899373–899382
3Section 01, James LevineDEF 14A2026-04-230001213037-26-000006Section “Summary Compensation Table”. As printed: 1,545,615. Filing ↗machine: r4 · c16 · span 886617–886626
4Section 03, James Levine OptionDEF 14A2026-04-230001213037-26-000006Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t22 · r3 · c9 · span 843159–843166
5Section 03, Mark Erlander OptionDEF 14A2026-04-230001213037-26-000006Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t22 · r2 · c9 · span 838863–838872
6Section 03, Roger Sidhu OptionDEF 14A2026-04-230001213037-26-000006Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t22 · r4 · c9 · span 847447–847456
7Section 07, pay ratio10-K2026-02-240001193125-26-067464Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Rodney S. MarkinDEF 14A2026-04-230001213037-26-000006Section “Director Compensation”. As printed: 225,670. Filing ↗machine: span 395622–395831
9Section 08, Lale WhiteDEF 14A2026-04-230001213037-26-000006Section “Director Compensation”. As printed: 189,170. Filing ↗machine: t8 · r7 · c11 · span 414689–414898
10Section 08, Gary W. PaceDEF 14A2026-04-230001213037-26-000006Section “Director Compensation”. As printed: 184,170. Filing ↗machine: span 405153–405362
11Section 08, Mani MohindruDEF 14A2026-04-230001213037-26-000006Section “Director Compensation”. As printed: 183,670. Filing ↗machine: span 400388–400597
12Section 08, Renee P. TannenbaumDEF 14A2026-04-230001213037-26-000006Section “Director Compensation”. As printed: 181,670. Filing ↗
13Section 08, James O. ArmitageDEF 14A2026-04-230001213037-26-000006Section “Director Compensation”. As printed: 175,670. Filing ↗machine: span 390842–391051
14Section 02, Ajay Aggarwal 2026-04-27Form 42026-04-280002132312-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Gary W. Pace 2026-06-11Form 42026-06-150001184778-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Rodney S. Markin 2026-06-11Form 42026-06-150001393415-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Renee P. Tannenbaum 2026-06-11Form 42026-06-150001543174-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Lale White 2026-06-11Form 42026-06-150001635493-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, James O. Armitage 2026-06-11Form 42026-06-150001370087-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Mani Mohindru 2026-06-18Form 42026-06-220001664708-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Gary W. Pace 2026-06-18Form 42026-06-220001184778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Mani Mohindru 2026-07-14Form 42026-07-160001193125-26-306072Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Gary W. Pace 2026-07-14Form 42026-07-160001193125-26-306083Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Gary W. Pace 2026-07-14Form 42026-07-160001193125-26-306083Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Mani Mohindru 2026-07-14Form 42026-07-160001193125-26-306072Insider equity transaction reported since the proxy statement. Filing ↗
26Section 06, 2026 voteForm 8-K2026-06-110001193125-26-267563Item 5.07 · say-on-pay result. As reported: 90.62% (votes for as printed: 17,120,176). Filing ↗
27Section 06, 2025 voteForm 8-K2025-06-260001641172-25-016659Item 5.07 · say-on-pay result. As reported: 87.99% (votes for as printed: 18,881,817). Filing ↗
28Section 06, 2024 voteForm 8-K2024-06-200001628280-24-029108Item 5.07 · say-on-pay result. As reported: 86.17% (votes for as printed: 13,280,919). Filing ↗
29Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
30Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
31Section 09b board cost (computed)Computed——Cash 500,000 + equity 0 + all other 0 = 500,000, summed across the director compensation table rows.machine: formula: Σ = 500,000
32Structure, Section 10b CEO totalDEF 14A2026-04-230001104659-26-047740CEO total compensation as printed in Structure's own proxy. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936
33Cardiff Oncology (subject), Section 10b CEO totalDEF 14A2026-04-230001213037-26-000006CEO total compensation as printed in Cardiff Oncology's own proxy. As printed: 3,023,344. Filing ↗machine: r2 · c16 · span 873925–873934
34Section 10a, Structure reciprocityDEF 14A—0001104659-26-047740Structure's most recent proxy was read; its disclosed peer group does not include Cardiff Oncology. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.